v3.26.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2025
Apr. 27, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description Filed to amend Items 10 through 14    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 001-39126    
Entity Registrant Name CNS Pharmaceuticals, Inc.    
Entity Central Index Key 0001729427    
Entity Tax Identification Number 82-2318545    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 2100 West Loop South    
Entity Address, Address Line Two Suite 900    
Entity Address, City or Town Houston    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 77027    
City Area Code 800    
Local Phone Number 946-9185    
Title of 12(b) Security Common Stock    
Trading Symbol CNSP    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 8,780,000
Entity Common Stock, Shares Outstanding   811,449  
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Insider Trading Policies and Procedures Adopted [Flag] true    
Award Timing MNPI Disclosure [Text Block] We do not grant equity awards in anticipation of the release of material nonpublic information that is likely to result in changes to the price of our common stock, and do not time the public release of such information based on award grant dates. During the last completed fiscal year, we have not made awards to any named executive officer or director during the period beginning four business days before and ending one business day after the filing of a period report on Form 10-Q or Form 10-K or the filing or furnishing of a current report on Form 8-K, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.    
Award Timing MNPI Considered [Flag] true